Tepezza Hearing Loss Lawsuit
Harding Mazzotti, LLP is currently investigating Tepezza, an infusion drug therapy intended for the treatment of Thyroid Eye Disease, which also includes conditions such as Graves’ Eye Disease, Graves’ Ophthalmopathy, or Graves’ Orbitopathy. Tepezza (also known as teprotumumab), manufactured by Horizon Pharmaceuticals, Inc., was approved by the U.S. Food and Drug Administration in January of 2020.
Tepezza & Hearing Loss
Patients who used Tepezza in clinical trials prior to FDA approval reported hearing loss and impairment as well as tinnitus (ringing in the ears) following its use. While acknowledging the potential side effects of hearing loss/damage throughout the FDA review process, Horizon characterized the issues as only temporary hearing loss, limited in duration, and affecting only 10% of the patients. However, The Journal Endocrine Society published a study in March 2021 revealing that 65% of individuals who used Tepezza experienced some degree of hearing loss, hearing damage, or tinnitus.
Furthermore, in February of 2022, an observational study published by the American Journal of Ophthalmology found that, in contrast to Horizon’s assertion that the hearing impairment was temporary, 3 out of 5 patients with Tepezza-related hearing loss had persistent subjective hearing-loss at their last follow-up appointments.
Tepezza Hearing Loss Lawsuits
Lawsuits are presently being filed against Horizon for its failure to properly warn doctors and patients about this known risk of permanent hearing loss and other hearing impairment injuries from the usage of Tepezza.
Get Help from a Tepezza Lawyer
If you or a loved one took Tepezza for treatment of thyroid eye disease and subsequently suffered hearing damage, hearing loss, or tinnitus, the attorneys at Harding Mazzotti, LLP are here for you. Contact us today for a free consultation at 1-800-LAW-1010 – we are available 24/7.